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Abstract
Worldwide, methicillin-resistant Staphylococcus aureus (MRSA) pose an increased risk for healthcare- and community-
associated infections. Since the first report of MRSA in England in 1961, several distinct clones or strains have emerged.
Changes within the MRSA population of whole countries, small regions or of single hospitals have been observed with some
clones replacing others. In this study, the clonal replacement of MRSA isolates in a South-eastern German tertiary care
hospital between 2000 and 2010 is described based on microarray analyses of 778 isolates and at least 50 MRSA per year.
Within these eleven years, four common epidemic strains, CC22-MRSA-IV, CC45-MRSA-IV, CC5/ST228-MRSA-I (including a
variant with a truncated SCCmec element) and CC5-MRSA-II were identified. The PVL-negative CC22-MRSA-IV strain (Barnim
Epidemic Strain, UK-EMRSA-15) was detected for the first time in 2001 and its abundance increased since then to 58.6% in
2010. CC5-MRSA-II increased from 2% (2000) to about 30% (2003), and since then it fluctuates between 23 and 37% of
isolates. CC5/ST228-MRSA-I decreased from about the half of tested isolates (2000) to 2.3% (2010). A similar trend was
observed for CC45-MRSA-IV, which decreased drastically down to 3.4% in 2010 after reaching a maximum of 62.0% in 2002.
Seventeen other PVL-negative MRSA strains were identified sporadically with no significant trend being observed. Seven
PVL-positive MRSA strains were found, but they remained rare during the study period accounting together for 2.7% of
isolates.
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Introduction
Shortly after the introduction of methicillin, first resistant
isolates were observed in England [1]. Within the last fifty years,
methicillin-resistant Staphylococcus aureus (MRSA) spread over the
whole world. Resistance to methicillin is caused by an alternative
penicillin-binding protein (PBP2a, [2]). It is encoded by mecA,
which is located within mobile genetic elements known as
‘‘staphylococcal cassette chromosomes’’ mec (SCCmec, [3–7]).
These are genomic islands of variable size (21–67 kb) always
integrating at the same site on the S. aureus genome. Since these
elements are mobile, unrelated strains might harbour the same
SCCmec elements and otherwise related strains might differ in
carriage of different SCCmec elements. With an increasing number
of co-circulating MRSA strains, it can be expected that strains are
in competition to each other. Strains which are less fit or less
adapted to their environment thus should be replaced and a
Darwinian evolution should take place within the global MRSA
population. Although factors determining failure or success of
individual clones have not yet been fully understood, it has been
noted that MRSA epidemiology and population structure
profoundly changed during the last two decades. Originally,
MRSA was restricted to hospitals where few, multiresistant strains
dominated (hospital-acquired or -associated MRSA, haMRSA).
The abundance of these strains is directly influenced by hospital
infection control practices, staff/patient ratio [8] and antibiotic
usage as well as by patient risk factors. Since the mid-1990s, so-
called community-associated MRSA (caMRSA) strains emerged
spreading among healthy individuals outside of hospitals. Some of
these strains [9] carry Panton-Valentine leukocidin (PVL), a long
known [10,11] virulence factor which is associated with chronic/
recurrent skin and soft tissue infections. Another recent develop-
ment is the spread of MRSA among livestock and people with
animal contact (livestock-associated MRSA, laMRSA; [12–14]).
As a result of these developments, changes within the MRSA
population structure of hospitals, regions and whole countries were
observed. A well documented example is Ireland. From 1971 to
2002, CC8/ST250-MRSA-I got replaced by ST239-MRSA-III
which in turn was replaced by CC5-MRSA-II, ST8-MRSA-IIA/
B/C/D/E, ST8-MRSA-(IV+ccrA/B-4) [15] and by CC22-MRSA-
IV, which is now the predominating strain [16,17]. Portuguese
studies show a replacement of ST239-MRSA-III by CC8/ST247-
MRSA-I which later was replaced by another variant of ST239-
MRSA-III. The latter one was later, after 2002, marginalised by
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emerge [18–20]. In Japan, PVL-positive CC30-MRSA-IV got
replaced by CC5-MRSA-II in the early 1990s [21]. Similar
observations have been made in Mexico [22] and in Hungary,
where CC5/ST228-MRSA-I and CC5-MRSA-II superseded
CC8/ST239-MRSA-III [23].
The aim of the present study was to monitor changes of clonal
affiliations of MRSA in a German university hospital over a period
of eleven years. For that purpose, a large number of isolates (30–
50% of all isolates of a given year) were characterised and assigned
to epidemic strains.
Results
From 2000 to 2010, 778 isolates were genotyped, i.e., isolates of
one-third to one-half of all MRSA patients identified during each
year of the study period (Table 1). An overview on detected strains
by year is given in Table 2. Full hybridisation profiles are provided
as online file S1.
CC22-MRSA-IV (Barnim Epidemic MRSA)
The most common strain, to which 270 isolates (34.7%)
belonged, was a PVL-negative CC22-MRSA-IV, known as
Barnim EMRSA or UK-EMRSA-15. 193 isolates originated from
male patients (72.0%, two anonymous cases excluded). The mean
age of patients was 65 years and their median age was 69 years.
23.4% of isolates came from intensive care units (ICUs), 51.3%
from wards and 11.9% from outpatient departments or emergency
rooms (OPD/ER).
Beside SCCmec IV (2B), CC22-MRSA-IV nearly always carried
blaZ (beta-lactamase). The macrolide/clindamycin resistance gene
erm(C) was found in about half of isolates (51.5%). Other resist-
ance genes were rare, being detectable in less than 2% of isolates.
This included tet(K) and tet(M) (tetracycline resistance), aadD
(tobramycin), aacA-aphD (gentamicin) as well as qacC (quaternary
ammonium compounds). The gene mupA, encoding high-level
mupirocin resistance, was not found.
CC22-MRSA-IV belonged to agr group I and capsule type 5.
Isolates always harboured the enterotoxin gene cluster egc com-
prising genes seg, sei, selm, seln, selo and selu/sely. Enterotoxin genes
C( sec) and L (sel) were found together in 14.1% of isolates.
CC5-MRSA-II (Rhine-Hesse EMRSA)
Approximately one out of four tested isolates (202 isolates,
26.0%) belonged to CC5-MRSA-II, also known as Rhine-Hesse
EMRSA, New York-Japan Clone or UK-EMRSA-3. 134 isolates,
i.e., 66.3% were obtained from male patients. The mean age of
patients was 59 years, the median age 65 years. 34.3% of isolates
originated from ICUs, while 54.2% came from wards and 11.4%
from OPD/ER.
The macrolide/clindamycin resistance gene erm(A) was present
in all isolates and 80.2% carried aadD. The beta-lactamase gene
blaZ was common (81.2%). In contrast, aacA-aphD, tet(M) and
tet(K) as well as a gene for resistance to quaternary ammonium
compounds, qacA, were very rare being detectable in less than one
percent of isolates. The mupA gene was not found.
Isolates of this strain belonged to agr group II and capsule type
5. All isolates carried the egc cluster. Furthermore, enterotoxin
genes D (sed), J (sej) and R (ser) were commonly detected (85.1%) as
well as a distinct variant of the enterotoxin A gene (sea-N315,
92.1%).
Table 1. Isolate numbers per year and patient demographics.
Year
Isolates
tested
Total number
of patients
with MRSA
in that year
Coverage
in %
Originated
from
OPD/ER
Originated
from
standard
wards
Originated
from ICU
Gender
ratio,
male:female
Age
.=15
Age
16–30
Age
31–45
Age
46–60
Age
.61
2000 51 112 45.5% 11 (21.6%) 19 (37.3%) 21 (41.2%) 31:20
(60.8:39.2%)
0 (0.0%) 2 (3.9%) 3 (5.9%) 16 (31.4%) 30 (58.8%)
2001 50 155 32.3% 14 (28.0%) 20 (40.0%) 16 (32.0%) 36:14
(72.0:28.0%)
3 (6.0%) 5 (10.0%) 6 (12.0%) 10 (20.0%) 26 (52.0%)
2002 54 149 36.2% 11 (20.4%) 27 (50.0%) 15 (27.8%) 38:16
(70.4:29.6%)
2 (3.7%) 4 (7.4%) 8 (14.8%) 9 (16.7%) 30 (55.6%)
2003 58 170 34.1% 17 (29.3%) 30 (51.7%) 10 (17.2%) 39:19
(67.2:32.8%)
2 (3.4%) 5 (8.6%) 4 (6.9%) 15 (25.9%) 31 (53.4%)
2004 59 150 39.3% 17 (28.8%) 33 (55.9%) 9 (15.3%) 43:16
(72.9:27.1%)
4 (6.8%) 7 (11.9%) 3 (5.1%) 13 (22.0%) 32 (54.2%)
2005 59 136 43.4% 14 (23.7%) 37 (62.7%) 8 (13.6%) 43:16
(72.9:27.1%)
5 (8.5%) 7 (11.9%) 5 (8.5%) 11 (18.6%) 32 (54.2%)
2006 60 114 52.6% 15 (25.0%) 31 (51.7%) 14 (23.3%) 36:24
(60.0:40.0%)
3 (5.0%) 3 (5.0%) 5 (8.3%) 12 (20.0%) 37 (61.7%)
2007 109 203 53.7% 31 (28.4%) 53 (48.6%) 25 (22.9%) 73:36
(67.0:33.0%)
5 (4.6%) 6 (5.5%) 8 (7.3%) 16 (14.7%) 74 (67.9%)
2008 106 201 52.7% 9 (8.5%) 50 (47.2%) 47 (44.3%) 74:32
(69.8:30.2%)
10 (9.4%) 0 (0.0%) 10 (9.4%) 13 (12.3%) 73 (68.9%)
2009 85 197 43.1% 21 (24.7%) 45 (52.9%) 19 (22.4%) 59:26
(69.4:30.6%)
1 (1.2%) 3 (3.5%) 4 (4.7%) 16 (18.8%) 60 (70.6%)
2010 87 205 42.4% 14 (16.1%) 52 (59.8%) 21 (24.1%) 63:22
(72.4:25.3%)
1 (1.1%) 5 (5.7%) 3 (3.4%) 27 (31.0%) 50 (57.5%)
If numbers for age/gender/ward affiliation do not add up to 100%, data were not available (anonymised samples from infection control unit; one case in 2002 and 2003,
two cases in 2010). OPD/ER, outpatient departments and emergency rooms; ICU, intensive care units.
doi:10.1371/journal.pone.0028189.t001
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Approximately one fourth (174 isolates or 22.4%) of the isolates
were identified as CC45-MRSA-IV, or Berlin EMRSA. Two-
thirds of these isolates (n=116) came from male patients. The
mean age of patients was 61 years, and their median age was 63
years. 17.2% of isolates originated from ICUs, while 53.4% came
from wards and 29.3% from OPD/ER.
The carriage of resistance genes in this strain was rather diverse.
Neomycin/kanamycin and streptothricin resistance genes aphA3
and sat were usually present (92.5%). Erm(C) was found in 24.7%
of the tested isolates, while erm(A) was rarely detected (1.7%).
Other resistance markers included aadD (5.7%), aacA-aphD
(13.2%), qacA (8.6%), qacC (10.6%), mupA (2.9%) as well as, in
less than 2% of isolates, cat (encoding resistance against chlor-
amphenicol), far1 (fusidic acid resistance), tet(M) and tet(K).
Berlin EMRSA isolates belonged to agr type I and capsule type
8. All isolates harboured the enterotoxin gene cluster egc although
the enterotoxin gene seg was deleted from 52.3% of isolates.
Enterotoxin genes sec and sel were occasionally found (2.9%). A
single isolate was found to be positive for the ACME locus
(encoding an arginine metabolic pathway which might play a role
in survival on intact skin [24]).
CC5/ST228-MRSA-I (South German EMRSA)
The fourth frequent strain was CC5/ST228-MRSA-I or South
German EMRSA to which 57 isolates (7.3%) were assigned. Forty-
six isolates, or 80.7%, originated from male patients. The mean
age of patients was 58 and their median age 60 years. 50.9% of
isolates came from ICUs, 35.1% from wards and 14.0% from
OPD/ER.
Table 2. Strain affiliations of characterised isolates by year.
Strain Total 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
CC22-MRSA-IV 270
(34.7%)
0 (0%) 3 (6%) 8 (14.8%) 10 (17.2%) 20 (33.9%) 16 (27.1%) 24 (40%) 52 (47.7%) 44 (41.5%) 42 (49.4%) 51 (58.6%)
CC5-MRSA-II 202 (26%) 1 (2%) 5 (10%) 5 (9.3%) 17 (29.3%) 20 (33.9%) 21 (35.6%) 17 (28.3%) 25 (22.9%) 39 (36.8%) 29 (34.1%) 23 (26.4%)
CC45-MRSA-IV 174
(22.4%)
19 (37.3%) 31 (62%) 34 (63%) 24 (41.4%) 13 (22%) 12 (20.3%) 12 (20%) 10 (9.2%) 13 (12.3%) 3 (3.5%) 3 (3.4%)
CC5/ST228-MRSA-I 32 (4.1%) 1 (2%) 1 (2%) 3 (5.6%) 3 (5.2%) 0 (0%) 4 (6.8%) 2 (3.3%) 12 (11%) 3 (2.8%) 1 (1.2%) 2 (2.3%)
CC5/ST228-MRSA-
trunc.SCCmec
25 (3.2%) 24 (47.1%) 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CC1-MRSA-IV 6 (0.8%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 1 (0.9%) 0 (0%) 1 (1.2%) 2 (2.3%)
CC5-MRSA-IV 6 (0.8%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 1 (1.7%) 2 (3.4%) 0 (0%) 1 (0.9%) 0 (0%) 1 (1.2%) 0 (0%)
CC5-MRSA-IV/VI 1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CC7-MRSA-IV 1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0 (0%)
CC8/ST247-MRSA-I 1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CC8/ST239-MRSA-III 6 (0.8%) 0 (0%) 5 (10%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0 (0%)
CC8-MRSA-IV
(Lyon clone)
5 (0.6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 4 (3.7%) 0 (0%) 0 (0%) 0 (0%)
CC8-MRSA-IV
(UK-EMRSA-14)
1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0 (0%)
CC8-MRSA-IV (USA500) 3 (0.4%) 0 (0%) 0 (0%) 1 (1.9%) 0 (0%) 0 (0%) 2 (3.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CC8/ST72-MRSA-IV 1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.2%) 0 (0%)
CC8-MRSA-V 1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CC8/ST254-MRSA-IV/V 3 (0.4%) 1 (2%) 2 (4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CC8/ST254-MRSA-atyp.
SCCmec
8 (1%) 4 (7.8%) 1 (2%) 1 (1.9%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0 (0%)
CC22-MRSA-V 2 (0.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.2%) 1 (1.1%)
CC30/ST36-MRSA-II 1 (0.1%) 0 (0%) 0 (0%) 1 (1.9%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
CC88-MRSA-IV 1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0 (0%)
CC97-MRSA-IV 1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0 (0%) 0 (0%)
CC398-MRSA-V 6 (0.8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 0 (0%) 1 (0.9%) 3 (3.5%) 1 (1.1%)
PVL-pos. CC1/ST772-
MRSA-V
2 (0.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.2%) 1 (1.1%)
PVL-pos. CC8-MRSA-IV
(USA300)
4 (0.5%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 0 (0%) 1 (0.9%) 2 (2.4%) 0 (0%)
PVL-pos. CC22-MRSA-IV 3 (0.4%) 1 (2%) 1 (2%) 1 (1.9%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PVL-pos. CC30-MRSA-IV 2 (0.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 1 (0.9%) 0 (0%) 0 (0%) 0 (0%)
PVL-pos. CC59-MRSA-VT1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0.9%) 0 (0%) 0 (0%) 0 (0%)
PVL-pos. CC80-MRSA-IV 8 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 3 (5.1%) 0 (0%) 1 (1.7%) 1 (0.9%) 0 (0%) 0 (0%) 3 (3.4%)
PVL-pos. CC152-MRSA-V1 (0.1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
doi:10.1371/journal.pone.0028189.t002
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the others lacked cassette chromosome recombinase A and B
genes (ccrA/B-1). With regard to antibiotic resistance markers,
virtually all isolates tested carried blaZ (93.0%), aphA3+sat (98.2%)
as well as erm(A) (94.7%) and aacA-aphD (94.7%). Neither mupA nor
other resistance genes were found.
CC5/ST228-MRSA-I isolates belonged to agr group II and
capsule type 5. The egc-cluster was usually present. However, in
24% of isolates of that strain, a large part of the egc-cluster (seg, sei,
selm, seln and selu/sely) was deleted together with the neighbouring
leukocidin genes lukD/E. The enterotoxin A gene, sea, was
detected in a majority of isolates of the variant with a normal
SCCmec I element (30 out of 32). It was always absent in isolates
with a truncated SCCmec element.
Sporadic PVL-negative strains
Beside the four common strains, another seventeen rare PVL-
negative strains were identified.
A PVL-negative CC1-MRSA-IV strain was sporadically
identified which was identical to West Australian (WA) MRSA-
1/57 [25].
Sporadic CC5 strains included CC5-MRSA-IV (Paediatric
clone). One isolate of a CC5/ST73-MRSA, associated with a
journey to the Canary Islands, Spain, apparently had a composite
SCCmec element yielding hybridisation signals for mecA, delta mecR,
ugpQ, Q9XB68-dcs, ccrA-2, ccrB-2, ccrA-4 and ccrB-4 (referred to as
CC5/ST73-MRSA-IV/VI).
Several strains belonged to CC8. The North German/Iberian
clone CC8/ST247-MRSA-I was identified in a single case of a
neurosurgical patient. A pandemic strain known as CC8/ST239-
MRSA-III or Vienna/Hungarian/Brazilian clone was found
infrequently, being involved in one outbreak and one isolated
case (see below). Several PVL-negative CC8-MRSA-IV strains
were discerned based on enterotoxin gene carriage. This included
UK-EMRSA-14/WA-MRSA-5 (without enterotoxin genes), Lyon
Clone/UK-EMRSA-2 (sea and/or sed+sej+ser) and USA500
(seb+sek+seq). The most common of the PVL-negative sporadic
strains was CC8/ST254-MRSA, colloquially known as Hannover
EMRSA or UK-EMRSA-10. There were two variants of this
strain, which differed in SCCmec markers. One variant (referred to
as CC8/ST254-MRSA-IV/V) reacted with probes for mecA, delta
mecR, ugpQ, Q9XB68-dcs, ccrA-2, ccrB-2, ‘‘ccrAA’’ (a recombinase
analogue, [25]), ccrC and, rarely, for the mercury resistance
operon. The other variant yielded signals with probes for mecA,
delta mecR, ugpQ, Q9XB68-dcs and the mercury resistance operon.
One isolate of a CC8-MRSA-V was identified. An atypical CC8
strain, ST72-MRSA-IV, differed from other CC8 strains in the
presence of egc and of CC5-like alleles of several genes encoding
adhesion factors (bbp, sdrC, sdrD). It is known to occur in the USA
and Portugal (USA700; [26,27]). The travel history of this patient
was not available, but an English name suggested foreign
background.
Two isolates of a PVL-negative CC22-MRSA-V strain were
found. These carried the egc-cluster along with sec and sel. With
regard to resistance genes, tet(K) was present in both cases as well
as Q6GD50, a putative fusidic acid resistance gene.
The recently emerging CC398-MRSA-V was found in six
patients. This strain is mainly known from animals, especially from
pigs [12–14] although transmissions to humans occasionally were
observed. Indeed, one of the patients from this study (in 2010) was
a retired butcher.
Very rare strains included CC7-MRSA-IV, CC88-MRSA-IV
and CC30/ST36-MRSA-II which were found once each; CC97-
MRSA-IV was detected in two cases.
PVL-positive strains
Seven different PVL-positive strains were identified from a total
of 21 patients (2.7%). Exactly two-thirds were male. Patients were
clearly younger than other MRSA patients (mean, 32 years;
median, 28 years). Eighteen cases were skin and soft tissue
infections, i.e., abscesses, furuncles etc. One isolate was recovered
from a screening culture of a nasal swab. A high percentage of
isolates came from OPD/ER (42.9%) while 47.6% originated
from wards. Two isolates were recovered from bronchial
secretions of intensive care patients (9.5%) who have been
admitted for other reasons. Cases of necrotising pneumonia were
not observed.
Two isolates of the PVL-positive strain CC1/ST772-MRSA-V
(Bengal Bay Clone [28,29]) were found. One of them was
associated to a journey to India while for the other case no travel
history was recorded. This strain belongs according to the MLST
database to CC1. However, it differs from other CC1 strains in
absence of the enterotoxin H gene seh, in the presence of egc and in
agr and capsule types [25]. Isolates carried blaZ, msr(A), mph(C),
aacA-aphD, aphA3, sat, and in one isolate, erm(C). Beside PVL genes,
isolates harboured sea, sec and sel.
The PVL-positive CC8-MRSA-IV strain USA300, was identi-
fied four times only, and no evidence for a spread or expansion of
that clone was noted. Isolates carried the ACME locus and, in
75.0%, sek and seq. PVL-positive CC22-MRSA-IV were found
only three times, the last isolate in 2003. Two isolates of PVL-
positive CC30-MRSA-IV (Southwest Pacific or West Samoan
Phage Pattern Clone) were identified. Both cases presented with
furuncles or ‘‘infected insect bites’’. One isolate was gentamicin-
resistant, carrying aacA-aphD. A PVL-positive CC59-MRSA-VT
(or 5C2&5), also known as Taiwan Clone, was found once. This
strain harbours, beside PVL, enterotoxin genes seb, sek and seq as
well as erm(B), which is an otherwise rare macrolide/clindamycin
resistance determinant.
The most common PVL-positive strain, the CC80-MRSA-IV
(European caMRSA Clone) was found in eight cases. It is
characterised by carriage of virulence-associated genes edinB and
etD. Isolates of this strain carried usually plasmid-borne [30] beta-
lactamase, tet(K) and a fusidic acid resistance gene (far1).
CC152-MRSA-V was identified once. The isolate lacked
enterotoxin genes and it was positive for aacA-aphD (gentamicin
resistance gene).
Temporal changes in the MRSA population
Temporal changes in the MRSA population are presented in
Figure 1.
In 2000, about half of the tested isolates were assigned to CC5/
ST228-MRSA-I. The vast majority belonged to the variant with a
truncated SCCmec element. Approximately one third of MRSA
isolates were identified as CC45-MRSA-IV. The third common
strain was CC8/ST254-MRSA to which, both variants combined,
about 10.0% of isolates belonged. CC5-MRSA-II was rare (one
isolate, 2.0%). The Barnim EMRSA, i.e., PVL-negative CC22-
MRSA-IV was not found. However, one isolate proved to be a
PVL-positive CC22-MRSA-IV. Its isolation represents the earliest
detection of PVL-MRSA in the Dresden region, approximately
three years prior to the earliest yet described case [30].
In 2001, the most abundant strain was CC45-MRSA-IV, to
which nearly two-thirds of typed isolates belonged. CC5-MRSA-II
became more common (10.0%). The number of cases of CC5/
ST228-MRSA-I significantly decreased to just one isolate and the
variant with a truncated SCCmec element was not detected.
Several isolates of CC8/ST239-MRSA-III were found to be
identical to each other, and indeed they were epidemiologically
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accident and emergency admission in Greece. The prevalence of
CC8/ST254-MRSA remained nearly stable and the PVL-
negative CC22-MRSA-IV strain was noted for the first time
(6.0%, or three isolates each). The PVL-positive CC22-MRSA-IV
strain was found again in a single patient.
In 2002, the majority of isolates belonged to CC45-MRSA-IV.
The Barnim EMRSA became more common, reaching about
15%. Three isolates of CC5/ST228-MRSA-I where found which
carried un-truncated SCCmec I elements. Furthermore, miscella-
neous PVL-negative strains were identified including CC5-
MRSA-II, a CC8-MRSA-IV strain known as USA500, which
was isolated from a trauma patient repatriated from Zimbabwe,
and the only CC30/ST36-MRSA-II isolate identified during this
study. The PVL-positive CC22-MRSA-IV strain was isolated
once.
In 2003, less than half (41.4%) of MRSA isolates belonged to
CC45-MRSA-IV. Most of the remaining isolates were assigned to
CC5-MRSA-II (29.3%) and CC22-MRSA-IV (17.2%). CC5/
ST228-MRSA-I was found only four times, including a last
detection of the variant with the truncated SCCmec element.
Further sporadic strains included CC8/ST247-MRSA-I, CC8/
ST254-MRSA and CC5-MRSA-IV. PVL-positive strains were
not identified.
In 2004, the majority of isolates were assigned to CC5-MRSA-
II and CC22-MRSA-IV (33.9% each). In this year, the latter strain
began to occur in wards and outpatient departments caring for
patients with diabetic foot ulcers, where it was to become
abundant in the following years. Further 22.0% of isolates
belonged to CC45-MRSA-IV, including one ACME-positive
isolate. Another isolate was identified as PVL-negative CC5/
ST73-MRSA-IV/VI. This was acquired during a visit to the
Canary Islands, Spain. Four isolates (6.8%) were identified as
PVL-positive, three belonging to CC80-MRSA-IV and one to
CC152-MRSA-V. Two isolates of the former strain where
epidemiologically linked to each other, and an association to
journeys either to Italy or to Kosovo was assumed [30].
CC5-MRSA-II dominated in 2005 (33.9%). Other common
strains were CC45-MRSA-IV (20.3%), PVL-negative CC22-
MRSA-IV (27.1%) and CC5/ST228-MRSA-I (6.8%). Sporadic
strains included CC5-MRSA-IV as well as CC8-MRSA-IV
(USA500), the later probably being imported from Ethiopia.
The livestock-associated CC398-MRSA-V and the PVL-positive
CC8-MRSA-IV (USA300) were both identified for the first time
with one isolate each.
In 2006, PVL-negative CC22-MRSA-IV was the most common
strain (40.0%) followed by CC5-MRSA-II (28.3%) and CC45-
MRSA-IV (20.0%). CC5/ST228-MRSA-I has almost disap-
peared, being found only twice. One of these isolates was traced
back to an outbreak in another hospital nearby. Two PVL-positive
MRSA strains were identified as CC80-MRSA-IV and ST30-
MRSA-IV, respectively.
In 2007, approximately half of isolates (47.7%) belonged to the
PVL-negative CC22-MRSA-IV. A number of these isolates
originated from wards and outpatient departments specialised in
care of diabetic foot ulcers, where a chronic outbreak situation
emerged lasting until 2010. Nearly one quarter (22.9%) of isolates
belonged to CC5-MRSA-II. CC5/ST228-MRSA-I and CC45-
MRSA-IV were less common strains (11.0% and, respectively,
9.2%). CC8-MRSA-IV (Lyon clone) was found in four patients
(3.7%), one of whom already carried that strain in 2006. Three
PVL-positive isolates were assigned to CC80-MRSA-IV, CC30-
MRSA-IV and CC59-MRSA-VT.
PVL-negative CC22-MRSA-IV (41.5%) and CC5-MRSA-II
(36.8%) were almost equally abundant strains in 2008. CC45-
MRSA-IV accounted for 12.3% of the tested isolates. A decrease
of CC5/ST228-MRSA-I to three isolates was noted. Sin-
gle isolates of six further PVL-negative strains were identified
Figure 1. Temporal changes in the MRSA population.
doi:10.1371/journal.pone.0028189.g001
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tion during travel to Turkey) and CC398-MRSA-V. One isolate of
PVL-positive CC8-MRSA-IV (USA300) was found.
In 2009, Barnim EMRSA accounted for nearly the half of
MRSA cases (49.4%) showing predominance in medical/diabeto-
logical wards. Another 34.1% of isolates belonged to CC5-MRSA-
II. CC45-MRSA-II nearly disappeared (three isolates, 3.5%).
Another three isolates belonged to CC398-MRSA-V. Three PVL-
positive isolates were found (3.5%). One belonged to CC1/ST772-
MRSA-V and two to CC8-MRSA-IV (USA300).
In 2010, the PVL-negative CC22-MRSA-IV was again the
most prevalent strain to which more than the half (58.6%) of all
isolates belonged. The prevalence of CC5-MRSA-II decreased to
26.4%. As few as 3.4% of the isolates were identified as CC45-
MRSA-IV, while 2.3% belonged to CC5/ST228-MRSA-I. One
case of an infection with the livestock-associated CC398-MRSA-V
was diagnosed. PVL-positive strains included CC1/ST772-
MRSA-V, from a patient who travelled to India in 2009. The
PVL-positive CC80-MRSA-IV clone was identified three times.
Discussion
Four major epidemic strains show clear and distinct trends over
the study time (Table 2 and Figure 1). These strains are the PVL-
negative CC22-MRSA-IV (Barnim EMRSA) and CC5-MRSA-II
(Rhine-Hesse EMRSA), CC5/ST228-MRSA-I (South German
EMRSA, including a variant with a truncated SCCmec element)
and CC45-MRSA-IV (Berlin EMRSA). From 2000 to 2010, an
almost complete displacement of the latter two strains by the
former two was observed.
PVL-negative CC22-MRSA-IV (Barnim EMRSA) predo-
minated in recent years. This is a successful, pandemic strain
which is common to abundant in many European countries
[16,17,20,31–33]. In Germany, this strain was first detected in
1996 [34] and its prevalence increased ever since [35]. This
development is mirrored by our data according to which that
strain became increasingly common during the last decade.
CC5-MRSA-II was very rare in the beginning of the study
period and showed a marked increase. In very recent years it
seems to be decreasing. It is especially common in intensive care
and surgical units. Thus it might be that CC5-MRSA-II locally
displaced CC5/ST228-MRSA-I which formerly was common in
this type of wards. Future studies might show whether this strain is
in competition with Barnim EMRSA or if they might co-exist in
slightly different ecological niches.
CC5/ST228-MRSA-I decreased from approximately 50% to a
much lower rate fluctuating between 4% and 11% (2007). The
majority of the earlier isolates belonged to a distinct variant with a
truncated SCCmec element not yet described from other regions
[25]. This, as well as the high degree of homogeneity among these
isolates, suggests an outbreak situation involving several surgical
and medical departments prior to the start of the study period.
This variant disappeared after 2000/2001 and was found only
once ever since. More recent isolates of CC5/ST228-MRSA-I
might be associated to transfers from patients from a long-term
care facility nearby, in which this strain still regularly was found
(author’s unpublished observations and [36]).
CC45-MRSA-IV was found in Saxony as early as 1997–1999
[37,38]. It showed an initial increase accounting for as much as
about 60% of isolates in 2001/2002. Then, it decreased drastically
and it was only found sporadically in recent years. A possible
explanation on a local level is the move of the surgical wards and
ICUs into a new building in the end of 2002. However, as this
strain also used to be common in other units, this cannot be the
only reason for its demise. Besides, this trend was also noted in
nationwide surveys [35]. In other geographical regions, such as
Belgium, CC45-MRSA-IV was more recently still the predomi-
nant MRSA strain [39].
The remaining PVL-negative MRSA strains occurred only
sporadically and were so rare that no clear trends could be
observed. For some of these strains, trends have been noted in
other studies and it could be assumed that our observations mirror
these developments although numbers of isolates were small.
Examples are CC8/ST247-MRSA-I and CC8/ST254-MRSA.
The former strain was detected only once within this study. It has
been observed in the region prior to the start of the study period,
from 1995–1997 [38,40], probably being replaced by other strains
in the years before 2000, as indicated by nationwide data [35], too.
Observations from other countries [15,20,41,42] also show that
this strain is currently vanishing. CC8/ST254-MRSA was com-
mon until the 1990s in Germany and it was detected in Dresden in
1997, 1998 and 1999 [37,38]). While it largely disappeared from
human patients [35], this strain can still frequently detected among
horses [43,44]. Some globally important strains were conspicu-
ously rare. Infections with these strains might be travel associated,
as it was noted for CC8-MRSA-IV (USA500) which originated
from patients with travel histories to Ethiopia, Mozambique and
Zimbabwe. CC8/ST239-MRSA-III, which can be found essen-
tially everywhere in the world [25,45], was detected on two
occasions including one outbreak with an index patient who
acquired it in Greece, and one isolated case associated with
medical care in Turkey. Interestingly, this strain is common in the
geographically close Czech Republic [46,47]. Since many years of
intense cross-border traffic did not result in a significant spread
into Saxony, community-borne transmission of that strain could be
regarded as virtually non-existent. Contrarily, transmissions even
to distant countries by medical evacuations have been observed.
Examples include the 2001 outbreak described above as well as, at
a much larger scale, a decade-long outbreak in Ireland following
repatriation from Iraq of a single patient [48].
PVL-positive MRSA shows strong fluctuations which, because
of the small absolute number of cases, can be considered as
random. PVL-MRSA in the Dresden region did not show the
massive increase during the study period which was observed, e.g.,
in the USA or Australia during the same period. The least rare
PVL-positive MRSA was CC80-MRSA-IV. This strain occurs
across the Middle East and the Maghreb (North African) countries
[49–54] as well as Europe where it appears to be generally rare,
except in Greece [55]. The PVL-positive CC8-MRSA-IV
(USA300) is epidemic in the USA and became there the
predominant MRSA strain [56,57]. In contrast, we found this
strain in isolated cases only. Other European studies [58] did also
not observe a major increase. This difference might lead to the
hypothesis that the ecological niche of USA300 is already
occupied by another successful strain such as CC22-MRSA-IV,
despite it is PVL-negative. The earliest PVL-MRSA strain noted
in the study period was PVL-positive CC22-MRSA-IV, isolated as
early as 2000. A large scale nosocomial outbreak of PVL-positive
CC22-MRSA-IV has been described shortly after in Bavaria,
Germany [59]. This strain has in our study not been identified
anymore after 2003. This might co-incite with the rise of PVL-
negative CC22-MRSA-IV and thus it could be speculated whether
some cross-immunity between strains existed on a population
level. Other PVL-MRSA strains are epidemic in restricted
geographic regions and cases observed in Europe are usually
travel-associated [25,60,61]. In our study, detection of PVL-
positive CC30-MRSA-IV, CC59-MRSA-VT or CC1/ST772-
MRSA-V was often connected to previous journeys. Apparently,
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such importations. However, the prevalence of PVL-MRSA in the
population might be somewhat higher than expected from the
data of this study, as patients with superficial skin and soft tissue
infections, supposed insect or spider bites etc. might present rather
to primary care facilities than to a tertiary care hospital.
The general reasons, why MRSA strains vanish or prevail are
largely unknown. One factor could be the impact of SCCmec
elements on the replication of S. aureus cells. SCCmec I elements are
known to be associated with higher glucose consumption and
lower growth rate compared to strains carrying SCCmec IV
elements [62,63]. This could contribute to the widely noted demise
of SCCmec I strains [15,20,41,42,64] in a situation of competition
to other strains. However, no comparable data are available for
other SCCmec elements, and a displacement of one SCCmec IV
strain by another (such as of Berlin EMRSA by Barnim EMRSA)
cannot be explained by such a SCCmec-associated disadvantage.
Possible other reasons for a replacement of MRSA strains by
others might theoretically include specific host preferences,
differences in the resistance to antibiotics, in infectivity as well as
the ability to cope with environmental stress, the potential for
spread, or in virulence.
Gender preference, or a lack of it, is not likely to play a role in
determining the ‘‘success’’ of an epidemic strain. It has previously
been noted that a majority of MRSA patients was male [65–67].
In this study, two-thirds of patients were male, which was also the
case in three of the four common strains as well as in PVL-positive
strains. In one common strain (CC5/ST228-MRSA-I), the
proportion of male patients was even higher. While a strain
theoretically could become especially common when being able to
colonise females to a comparable extend as males, none of the
‘‘successful’’ strains showed this behaviour. Another host factor
could be the average age of the host population. Assuming a low
grade of transmission, MRSA strains would gradually pass away
together with the generation of hosts they actually reside in.
However, this is unlikely as the currently most successful strain in
our study (Barnim EMRSA) had the oldest host population.
Antibiotic resistance might be a factor in haMRSA, but many of
the recently emerging caMRSA are less resistant. It will be
interesting to watch in the future whether the exceptionally multi-
resistant caMRSA strain CC1/ST772-MRSA-V might have an
advantage compared to less resistant caMRSA strains. Changes in
treatment as well as in hygiene regimes or implementation of a
‘‘search and destroy’’ policy should affect mainly hospital-acquired
strains without having much impact on community- and livestock-
associated strains.
With regard to transmissibility/infectivity, it was suggested that
the presence of ACME contributed to the success of the USA300
strain [24,68]. However, ACME is abundant in coagulase-
negative staphylococci [69,70], but very rare in any S. aureus
other than USA300 [25]. Therefore, it still needs to be proven
whether it indeed confers a selective advantage to S. aureus.
Resistance to environmental stress, such as UV light, exsiccation
or to changing temperatures might also contribute to the
transmissibility and thus, to the success of a strain. Experimental
data are still needed to verify this.
The presence of virulence factors (PVL) might have played a
role in the spread of the USA300 strain. Contrarily, two other
successful strains, CC22-MRSA-IV and CC398-MRSA-V, appear
not to be particularly virulent, being negative for PVL, exfoliative
toxin genes, tst1 and, in case of CC398-MRSA-V, even for
enterotoxin genes.
It can be assumed that the abundance of MRSA is also
influenced by factors such as the presence of a susceptible host
population and the absence of specific bacteriophages. A newly
emerging strain might thus propagate unchecked until some kind
of herd immunity evolved or until specific bacteriophages spread.
Then it could be assumed that the rise and fall of MRSA strains
just mirrored temporal changes in the whole S. aureus population,
of which MRSA is just a fraction. In order to get a more complete
picture of the population dynamics it would be necessary to type
large collections of carriage isolates, including methicillin-suscep-
tible S. aureus, and monitor possible changes in their clonal
composition over extended periods of time. A better understand-
ing of S. aureus population dynamics might contribute to the
development of effective approaches to control and contain this
important pathogen.
Materials and Methods
Bacterial isolates
The study was performed at a tertiary care hospital in Dresden,
Saxony,i.e.,intheSouth-EasternpartofGermany.The hospitalhas
approximately 1,250 beds and treats 53,000 in-patients per year
(http://www.uniklinikum-dresden.de/das-klinikum/jahresbericht/
ukd_jahresbericht_2009.pdf). The total incidence density was 0.74
MRSA cases per 1,000 patient-days (2010) which means it was
below national average (1.14 MRSA cases per 1,000 patient-days,
http://www.nrz-hygiene.de/en/surveillance/hospital-infection-
surveillance-system/mrsa-kiss/421d00b8/627/720/).
MRSA isolates passed through standard clinical routine
diagnostics. Specimens included screening samples and diagnostic
samples from various infections. After primary culture and
subculturing of single colonies, screening for clumping factor
utilising the Pastorex StaphPlus kit was performed. Susceptibility
tests were performed by a standard agar dilution procedure or by
VITEK 1 or VITEK 2 systems (BioMerieux, Nuertingen,
Germany). Methicillin resistance was confirmed by detection of
PBP2a using the Innogenetics MRSA-screen agglutination assay
(Innogenetics, Ghent, Belgium). Isolates were stored frozen using
cryobank tubes (Microbank, Pro-Lab Diagnostics, Richmond Hill,
Canada) at 280uC. For this study, one-third of the preserved
isolates per year were chosen randomly and genotyped retrospec-
tively. In addition to that, isolates were included which have been,
largely prospectively, genotyped due to clinical or infection control
relevance. This included all MRSA isolates from ICUs and
diabetology wards, from suspected outbreak situations and from
clinical conditions suggesting involvement of PVL. Only one
isolate per patient and year was considered. Thus, one-third to
one-half of all MRSA isolates of a given year were genotyped.
Isolate numbers per year as well as patient demographics are
shown in Table 1.
DNA microarray-based typing
Most isolates were characterised using the Alere StaphyType
DNA microarray which covers 334 target sequences (approxi-
mately 170 distinct genes and their allelic variants) including
species markers, SCCmec, capsule and agr group typing markers,
resistance genes, exotoxin, set/ssl and MSCRAMM genes. Primer/
probe sequences have been provided previously [25]. Some of the
prospectively tested isolates, mainly of the years 2007–08, have
been tested using an older version of the array which covered less
target genes (see file S1). Protocols have been previously described
in detail [25,36,71] and are also provided by the kit manufacturer.
MRSA were grown on Columbia blood agar, harvested and
enzymatically lysed. DNA was prepared using commercially
available systems (spin columns or EZ1, Qiagen, Hilden,
Germany). DNA samples were used as templates in a linear
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tion, biotin-16-dUTP was incorporated into the amplicons. These
were hybridised to the microarray followed by the addition of
horseradish-peroxidase-streptavidin. Finally, hybridisations were
visualised by dye precipitation. An image of the microarray was
taken and analysed using a designated reader and software (Alere
Technologies GmbH, Jena, Germany) using a algorithm as
described previously [25]. This included the assignment of isolates
to clonal complexes (CC) or sequence types (ST), as defined by
MLST [72], and to epidemic strains by comparison of hybri-
disation profiles to a reference database. Epidemic MRSA strains
(EMRSA) were defined and named as in a previously published
study [19].
Sequence-based typing (MLST and spa)
Multilocus sequence typing (MLST) and spa typing procedures
were performed on selected isolates for confirmatory reasons
according to previously published protocols [72]. The sequences
were analysed using the MLST website (http://saureus.mlst.net/)
or, respectively, the Ridom nomenclature (http://spa.ridom.de/)
and the SPATYPEMAPPER software (freeware, download
at http://www.clondiag.com/fileadmin/Media/Downloads/
SPATypeMapper_0_6.zip).
Supporting Information
File S1 Patient data and full hybridisation profiles.
(PDF)
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